Dr. Curiel has over 18 years of biopharma industry experience in both US and Global Medical Affairs (GMA) leadership roles.
Prior to joining Xennials Therapeutics™ Inc., Dr. Curiel held key GMA roles at Eli Lilly, Wyeth, Pfizer, Bristol-Myers Squibb, Aveo Pharmaceuticals, Astellas and Celldex Therapeutics with direct responsibility of building and leading teams for the successful development and execution of medical strategies for the following products and assets: GEMZAR® (gemcitabine), ALIMTA® (pemetrexed), TORISEL® (temsirolimus), MYLOTARG® (gemtuzumab ozogamicin), BOSULIF® (bosutinib), NERLYNX® (neratinib), BESPONSA® (inotuzumab ozogamicin), OPDIVO® (nivolumab), SPRYCEL® (dasatinib), IXEMPRA® (ixabepilone), EVRI (BMS-690514), XTANDI® (enzalutamide), ELIGARD® (leuprolide acetate), FOTIVDA® (Tivozanib), Gilteritinib (ASP2215), Rindopepimut (CDX-110) and Glembatumumab vedotin (CDX-011).
Dr. Curiel holds a PhD in Immunology from the Biomedical Science Program at Wright State University (WSU), MS in Immunology/Microbiology from WSU and a BS in Microbiology from Louisiana State University. He also held Post-Doctoral Fellowship positions at the National Cancer Institute in Frederick, MD & Stanley Scott Cancer Center in New Orleans, LA.